1
|
Compendium on Food Crop Plants as a Platform for Pharmaceutical Protein Production. Int J Mol Sci 2022; 23:ijms23063236. [PMID: 35328657 PMCID: PMC8951019 DOI: 10.3390/ijms23063236] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 03/14/2022] [Accepted: 03/15/2022] [Indexed: 12/14/2022] Open
Abstract
Tremendous advances in crop biotechnology related to the availability of molecular tools and methods developed for transformation and regeneration of specific plant species have been observed. As a consequence, the interest in plant molecular farming aimed at producing the desired therapeutic proteins has significantly increased. Since the middle of the 1980s, recombinant pharmaceuticals have transformed the treatment of many serious diseases and nowadays are used in all branches of medicine. The available systems of the synthesis include wild-type or modified mammalian cells, plants or plant cell cultures, insects, yeast, fungi, or bacteria. Undeniable benefits such as well-characterised breeding conditions, safety, and relatively low costs of production make plants an attractive yet competitive platform for biopharmaceutical production. Some of the vegetable plants that have edible tubers, fruits, leaves, or seeds may be desirable as inexpensive bioreactors because these organs can provide edible vaccines and thus omit the purification step of the final product. Some crucial facts in the development of plant-made pharmaceuticals are presented here in brief. Although crop systems do not require more strictly dedicated optimization of methodologies at any stages of the of biopharmaceutical production process, here we recall the complete framework of such a project, along with theoretical background. Thus, a brief review of the advantages and disadvantages of different systems, the principles for the selection of cis elements for the expression cassettes, and available methods of plant transformation, through to the protein recovery and purification stage, are all presented here. We also outline the achievements in the production of biopharmaceuticals in economically important crop plants and provide examples of their clinical trials and commercialization.
Collapse
|
2
|
Shanmugaraj B, I. Bulaon CJ, Phoolcharoen W. Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. PLANTS 2020; 9:plants9070842. [PMID: 32635427 PMCID: PMC7411908 DOI: 10.3390/plants9070842] [Citation(s) in RCA: 105] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 06/20/2020] [Accepted: 06/30/2020] [Indexed: 12/20/2022]
Abstract
The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed.
Collapse
Affiliation(s)
- Balamurugan Shanmugaraj
- Research Unit for Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand;
- Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok 10330, Thailand;
| | - Christine Joy I. Bulaon
- Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok 10330, Thailand;
| | - Waranyoo Phoolcharoen
- Research Unit for Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand;
- Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok 10330, Thailand;
- Correspondence: ; Tel.: +66-2-218-8359; Fax: +66-2-218-8357
| |
Collapse
|
3
|
Wesołowska A, Kozak Ljunggren M, Jedlina L, Basałaj K, Legocki A, Wedrychowicz H, Kesik-Brodacka M. A Preliminary Study of a Lettuce-Based Edible Vaccine Expressing the Cysteine Proteinase of Fasciola hepatica for Fasciolosis Control in Livestock. Front Immunol 2018; 9:2592. [PMID: 30483259 PMCID: PMC6244665 DOI: 10.3389/fimmu.2018.02592] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 10/22/2018] [Indexed: 11/16/2022] Open
Abstract
Oral vaccination with edible vaccines is one of the most promising approaches in modern vaccinology. Edible vaccines are an alternative to conventional vaccines, which are typically delivered by injection. Here, freeze-dried transgenic lettuce expressing the cysteine proteinase of the trematode Fasciola hepatica (CPFhW) was used to orally vaccinate cattle and sheep against fasciolosis, which is the most important trematode disease due to the parasite's global distribution, wide spectrum of host species and significant economic losses of farmers. In the study, goals such as reducing the intensity of infection, liver damage and F. hepatica fecundity were achieved. Moreover, we demonstrated that the host sex influenced the outcome of infection following vaccination, with female calves and male lambs showing better protection than their counterparts. Since differences occurred following vaccination and infection, different immunization strategies should be considered for different sexes and host species when developing new control methods. The results of the present study highlight the potential of oral vaccination with plant-made and plant-delivered vaccines for F. hepatica infection control.
Collapse
Affiliation(s)
- Agnieszka Wesołowska
- Polish Academy of Sciences, Witold Stefanski Institute of Parasitology, Warsaw, Poland
| | | | - Luiza Jedlina
- Polish Academy of Sciences, Witold Stefanski Institute of Parasitology, Warsaw, Poland
| | - Katarzyna Basałaj
- Polish Academy of Sciences, Witold Stefanski Institute of Parasitology, Warsaw, Poland
| | - Andrzej Legocki
- Polish Academy of Sciences, Institute of Bioorganic Chemistry, Poznan, Poland
| | - Halina Wedrychowicz
- Polish Academy of Sciences, Witold Stefanski Institute of Parasitology, Warsaw, Poland
| | | |
Collapse
|
4
|
Abstract
Plants and their rich variety of natural compounds are used to maintain and to improve health since the earliest stages of civilization. Despite great advances in synthetic organic chemistry, one fourth of present-day drugs have still a botanical origin, and we are currently living a revival of interest in new pharmaceuticals from plant sources. Modern biotechnology has defined the potential of plants to be systems able to manufacture not only molecules naturally occurring in plants but also newly engineered compounds, from small to complex protein molecules, which may originate even from non-plant sources. Among these compounds, pharmaceuticals such as vaccines, antibodies and other therapeutic or prophylactic entities can be listed. For this technology, the term plant molecular farming has been coined with reference to agricultural applications due to the use of crops as biofactories for the production of high-added value molecules. In this perspective, edible plants have also been thought as a tool to deliver by the oral route recombinant compounds of medical significance for new therapeutic strategies. Despite many hurdles in establishing regulatory paths for this “novel” biotechnology, plants as bioreactors deserve more attention when considering their intrinsic advantages, such as the quality and safety of the recombinant molecules that can be produced and their potential for large-scale and low-cost production, despite worrying issues (e.g. amplification and diffusion of transgenes) that are mainly addressed by regulations, if not already tackled by the plant-made products already commercialized. The huge benefits generated by these valuable products, synthesized through one of the safest, cheapest and most efficient method, speak for themselves. Milestone for plant-based recombinant protein production for human health use was the approval in 2012 by the US Food and Drug Administration of plant-made taliglucerase alfa, a therapeutic enzyme for the treatment of Gaucher’s disease, synthesized in carrot suspension cultures by Protalix BioTherapeutics. In this review, we will go through the various approaches and results for plant-based production of proteins and recent progress in the development of plant-made pharmaceuticals (PMPs) for the prevention and treatment of human diseases. An analysis on acceptance of these products by public opinion is also tempted.
Collapse
|
5
|
Singh A, Kaur G, Singh S, Singh N, Saxena G, Verma PC. Recombinant Plant Engineering for Immunotherapeutic Production. CURRENT MOLECULAR BIOLOGY REPORTS 2017; 3:306-316. [PMID: 32226727 PMCID: PMC7099902 DOI: 10.1007/s40610-017-0078-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE OF REVIEW The requirement for large quantities of therapeutic proteins has fueled a great interest in the production of recombinant proteins in plant bioreactors. The vaccines and bio-therapeutic protein production in plants hold the promise of significantly lowering the cost of manufacturing life-saving drugs. This review will reflect the current status and challenges that the molecular farming platform faces becoming a strategic solution for the development of low-cost bio-therapeutics for developing countries. RECENT FINDINGS Different plant parts have been successfully identified as suitable expression systems for the commercial production of therapeutic proteins for some human and animal diseases ranging from common cold to AIDS. The processed therapeutics from such sources are devoid of any toxic components. The large-scale cultivation of these transgenic plants would be possible anywhere in the world including developing countries, which lack sophisticated drug manufacturing units. A couple of such commercially generated products have already hit the market with success. Newer methods using suitable plant viruses and recombinant gene expression systems have already been devised for producing therapeutic proteins and peptides. SUMMARY Plants are promising bio-factories for therapeutic protein production because of their several advantages over the other expression systems especially the advanced mechanisms for protein synthesis and post-translational modification which are very much similar to animal cells. Plant biotechnologists are much attracted to the bio-farming because of its flexibility, scalability, low manufacturing cost, as well as the lack of risk of toxic or pathogenic contamination. A number of projects on bio-farming are designed and are at various developmental stages but have not yet become available to the pharmaceutical industry. Therefore, we need further advancement in the optimization of lab protocols for up-scaling the production of such therapeutics at commercial level with a promise to offer their best clinical use.
Collapse
Affiliation(s)
- Ankit Singh
- Department of Biosciences, Jamia Millia Islamia University, New Delhi, 110025 India
| | - Gurminder Kaur
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Sector 125, Noida, 201303 India
| | - Sanchita Singh
- Genetics and Plant Molecular Biology Division, CSIR-National Botanical Research Institute, Rana Pratap Marg, Lucknow, U.P 226001 India
| | - Neetu Singh
- Instrumentation Research Facility, Jawahar Lal Nehru University, New Delhi, 110067 India
| | - Gauri Saxena
- Department of Botany, University of Lucknow, Lucknow, 226001 India
| | - Praveen C. Verma
- Genetics and Plant Molecular Biology Division, CSIR-National Botanical Research Institute, Rana Pratap Marg, Lucknow, U.P 226001 India
| |
Collapse
|
6
|
Kesik-Brodacka M, Lipiec A, Kozak Ljunggren M, Jedlina L, Miedzinska K, Mikolajczak M, Plucienniczak A, Legocki AB, Wedrychowicz H. Immune response of rats vaccinated orally with various plant-expressed recombinant cysteine proteinase constructs when challenged with Fasciola hepatica metacercariae. PLoS Negl Trop Dis 2017; 11:e0005451. [PMID: 28333957 PMCID: PMC5383346 DOI: 10.1371/journal.pntd.0005451] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Revised: 04/06/2017] [Accepted: 03/02/2017] [Indexed: 12/07/2022] Open
Abstract
Background Cysteine proteinases of Fasciola hepatica are important candidates for vaccine antigens because of their role in fluke biology and host-parasite relationships. In our previous experiments, we found that a recombinant cysteine proteinase cloned from adult F. hepatica (CPFhW) can protect rats against liver fluke infections when it is administered intramuscularly or intranasally in the form of cDNA. We also observed considerable protection upon challenge following mucosal vaccination with inclusion bodies containing recombinant CPFhW produced in Escherichia coli. In this study, we explore oral vaccination, which may be the desired method of delivery and is potentially capable of preventing infections at the site of helminth entry. To provide antigen encapsulation and to protect the vaccine antigen from degradation in the intestinal tract, transgenic plant-based systems are used. Methodology In the present study, we aimed to evaluate the protective ability of mucosal vaccinations of 12-week-old rats with CPFhW produced in a transgenic-plant-based system. To avoid inducing tolerance and to maximise the immune response induced by oral immunisation, we used the hepatitis B virus (HBV) core protein (HBcAg) as a carrier. Animals were immunised with two doses of the antigen and challenged with 25 or 30 metacercariae of F. hepatica. Conclusions We obtained substantial protection after oral administration of the plant-produced hybrids of CPFhW and HBcAg. The highest level of protection (65.4%) was observed in animals immunised with transgenic plants expressing the mature CPFhW enzyme flanked by Gly-rich linkers and inserted into c/e1 epitope of truncated HBcAg. The immunised rats showed clear IgG1 and IgM responses to CPFhW for 4 consecutive weeks after the challenge. Infection with Fasciola hepatica, a liver fluke, is one of the most significant veterinary problems due to the worldwide distribution of this parasite, a wide spectrum of host organisms and the resulting economic loss. Human fasciolosis caused by F. hepatica is recognised by the World Health Organization as an important emerging but neglected tropical disease. Development of an effective vaccine against this disease is becoming a priority, especially as the appearance of drug-resistant strains undermine the currently employed drug-based treatments. The two primary issues when developing a vaccine are the selection of an appropriate vaccine antigen and the route of antigen administration. In our studies, we use one of the F. hepatica cysteine proteinases, which are promising antigens for vaccine construction. We evaluate the immunogenicity and protective ability of various modifications of this cysteine proteinase produced in plants. We show that substantial protection can be obtained when plant-expressed hybrid proteins are administered orally.
Collapse
Affiliation(s)
| | - Agnieszka Lipiec
- Division of Parasitology, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, Poland
| | | | - Luiza Jedlina
- Witold Stefański Institute of Parasitology, Polish Academy of Sciences, Warsaw, Poland
| | | | | | - Andrzej Plucienniczak
- Department of Bioengineering, Institute of Biotechnology and Antibiotics, Warsaw, Poland
| | - Andrzej B. Legocki
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
| | - Halina Wedrychowicz
- Witold Stefański Institute of Parasitology, Polish Academy of Sciences, Warsaw, Poland
| |
Collapse
|
7
|
Kumar N, Barua S, Riyesh T, Tripathi BN. Advances in peste des petits ruminants vaccines. Vet Microbiol 2017; 206:91-101. [PMID: 28161212 PMCID: PMC7130925 DOI: 10.1016/j.vetmic.2017.01.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Revised: 11/13/2016] [Accepted: 01/12/2017] [Indexed: 11/27/2022]
Abstract
Peste des petits ruminants (PPR) is a highly contagious disease of small ruminants that leads to high morbidity and mortality thereby results in devastating economic consequences to the livestock industry. PPR is currently endemic across most parts of Asia and Africa, the two regions with the highest concentration of poor people in the world. Sheep and goats in particularly contribute significantly towards the upliftment of livelihood of the poor and marginal farmers in these regions. In this context, PPR directly affecting the viability of sheep and goat husbandry has emerged as a major hurdle in the development of these regions. The control of PPR in these regions could significantly contribute to poverty alleviation, therefore, the Office International des Epizooties (OIE) and Food and Agricultural Organization (FAO) have targeted the control and eradication of PPR by 2030 a priority. In order to achieve this goal, a potent, safe and efficacious live-attenuated PPR vaccine with long-lasting immunity is available for immunoprophylaxis. However, the live-attenuated PPR vaccine is thermolabile and needs maintenance of an effective cold chain to deliver into the field. In addition, the infected animals cannot be differentiated from vaccinated animals. To overcome these limitations, some recombinant vaccines have been developed. This review comprehensively describes about the latest developments in PPR vaccines.
Collapse
Affiliation(s)
- Naveen Kumar
- National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, Haryana, India.
| | - Sanjay Barua
- National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, Haryana, India.
| | - Thachamvally Riyesh
- National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, Haryana, India
| | - Bhupendra N Tripathi
- National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, Haryana, India
| |
Collapse
|
8
|
The case for plant-made veterinary immunotherapeutics. Biotechnol Adv 2016; 34:597-604. [PMID: 26875776 DOI: 10.1016/j.biotechadv.2016.02.007] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 01/14/2016] [Accepted: 02/11/2016] [Indexed: 12/11/2022]
Abstract
The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.
Collapse
|
9
|
Takeyama N, Kiyono H, Yuki Y. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. THERAPEUTIC ADVANCES IN VACCINES 2015; 3:139-54. [PMID: 26668752 DOI: 10.1177/2051013615613272] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.
Collapse
Affiliation(s)
- Natsumi Takeyama
- Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Hiroshi Kiyono
- Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yoshikazu Yuki
- Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| |
Collapse
|
10
|
Krishna G, Singh BK, Kim EK, Morya VK, Ramteke PW. Progress in genetic engineering of peanut (Arachis hypogaea L.)--a review. PLANT BIOTECHNOLOGY JOURNAL 2015; 13:147-62. [PMID: 25626474 DOI: 10.1111/pbi.12339] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 11/27/2014] [Accepted: 12/17/2014] [Indexed: 05/20/2023]
Abstract
Peanut (Arachis hypogaea L.) is a major species of the family, Leguminosae, and economically important not only for vegetable oil but as a source of proteins, minerals and vitamins. It is widely grown in the semi-arid tropics and plays a role in the world agricultural economy. Peanut production and productivity is constrained by several biotic (insect pests and diseases) and abiotic (drought, salinity, water logging and temperature aberrations) stresses, as a result of which crop experiences serious economic losses. Genetic engineering techniques such as Agrobacterium tumefaciens and DNA-bombardment-mediated transformation are used as powerful tools to complement conventional breeding and expedite peanut improvement by the introduction of agronomically useful traits in high-yield background. Resistance to several fungal, virus and insect pest have been achieved through variety of approaches ranging from gene coding for cell wall component, pathogenesis-related proteins, oxalate oxidase, bacterial chloroperoxidase, coat proteins, RNA interference, crystal proteins etc. To develop transgenic plants withstanding major abiotic stresses, genes coding transcription factors for drought and salinity, cytokinin biosynthesis, nucleic acid processing, ion antiporter and human antiapoptotic have been used. Moreover, peanut has also been used in vaccine production for the control of several animal diseases. In addition to above, this study also presents a comprehensive account on the influence of some important factors on peanut genetic engineering. Future research thrusts not only suggest the use of different approaches for higher expression of transgene(s) but also provide a way forward for the improvement of crops.
Collapse
Affiliation(s)
- Gaurav Krishna
- Jacob School of Biotechnology & Bioengineering, Sam Higginbottom Institute of Agriculture, Technology & Sciences (Formerly Allahabad Agricultural Institute), Deemed University, Allahabad, Uttar Pradesh, India
| | | | | | | | | |
Collapse
|
11
|
Mucosal Vaccines from Plant Biotechnology. Mucosal Immunol 2015. [PMCID: PMC7158328 DOI: 10.1016/b978-0-12-415847-4.00065-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The use of plants for production of recombinant proteins has evolved over the past 25 years. The first plant-based vaccines were expressed in stably transgenic plants, with the idea to conveniently deliver “edible vaccines” by ingestion of the antigen-containing plant material. These systems provided a proof of concept that oral delivery of vaccines in crude plant material could stimulate antigen-specific serum and mucosal antibodies. Transgenic grains like rice in particular provide a stable and robust vehicle for antigen delivery. However, some issues exist with stably transgenic plants, including relatively low expression levels and regulatory issues. Thus, many recent studies use transient expression with plant viral vectors to achieve rapid high expression in Nicotiana benthamiana, followed by purification of antigen and intranasal delivery for effective stimulation of mucosal immune responses.
Collapse
|
12
|
Kolotilin I, Topp E, Cox E, Devriendt B, Conrad U, Joensuu J, Stöger E, Warzecha H, McAllister T, Potter A, McLean MD, Hall JC, Menassa R. Plant-based solutions for veterinary immunotherapeutics and prophylactics. Vet Res 2014; 45:117. [PMID: 25559098 PMCID: PMC4280687 DOI: 10.1186/s13567-014-0117-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 10/30/2014] [Indexed: 12/19/2022] Open
Abstract
An alarming increase in emergence of antibiotic resistance among pathogens worldwide has become a serious threat to our ability to treat infectious diseases according to the World Health Organization. Extensive use of antibiotics by livestock producers promotes the spread of new resistant strains, some of zoonotic concern, which increases food-borne illness in humans and causes significant economic burden on healthcare systems. Furthermore, consumer preferences for meat/poultry/fish produced without the use of antibiotics shape today's market demand. So, it is viewed as inevitable by the One Health Initiative that humans need to reduce the use of antibiotics and turn to alternative, improved means to control disease: vaccination and prophylactics. Besides the intense research focused on novel therapeutic molecules, both these strategies rely heavily on the availability of cost-effective, efficient and scalable production platforms which will allow large-volume manufacturing for vaccines, antibodies and other biopharmaceuticals. Within this context, plant-based platforms for production of recombinant therapeutic proteins offer significant advantages over conventional expression systems, including lack of animal pathogens, low production costs, fast turnaround and response times and rapid, nearly-unlimited scalability. Also, because dried leaves and seeds can be stored at room temperature for lengthy periods without loss of recombinant proteins, plant expression systems have the potential to offer lucrative benefits from the development of edible vaccines and prophylactics, as these would not require "cold chain" storage and transportation, and could be administered in mass volumes with minimal processing. Several biotechnology companies currently have developed and adopted plant-based platforms for commercial production of recombinant protein therapeutics. In this manuscript, we outline the challenges in the process of livestock immunization as well as the current plant biotechnology developments aimed to address these challenges.
Collapse
Affiliation(s)
- Igor Kolotilin
- />Department of Biology, University of Western Ontario, 1151 Richmond St, London, ON Canada
| | - Ed Topp
- />AAFC, Southern Crop Protection and Food Research Centre, 1391 Sandford St, London, ON Canada
| | - Eric Cox
- />Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
| | - Bert Devriendt
- />Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
| | - Udo Conrad
- />Leibniz Institute of Plant Genetics and Crop Plant Research, Gatersleben, Germany
| | - Jussi Joensuu
- />VTT Technical Research Centre of Finland, Espoo, Finland
| | - Eva Stöger
- />Department for Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Heribert Warzecha
- />Technische Universität Darmstadt, FB Biologie, Schnittspahnstr. 5, D-64287 Darmstadt, Germany
| | - Tim McAllister
- />AAFC, Lethbridge Research Centre, 5403, 1 Avenue South, Lethbridge, Alberta Canada
| | - Andrew Potter
- />Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan Canada
- />Department of Veterinary Microbiology, University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan Canada
| | - Michael D McLean
- />PlantForm Corp., c/o Room 2218, E.C. Bovey Bldg, University of Guelph, Guelph, Ontario N1G 2 W1 Canada
| | - J Christopher Hall
- />School of Environmental Sciences, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G 2 W1 Canada
| | - Rima Menassa
- />Department of Biology, University of Western Ontario, 1151 Richmond St, London, ON Canada
- />AAFC, Southern Crop Protection and Food Research Centre, 1391 Sandford St, London, ON Canada
| |
Collapse
|
13
|
Ling HY, Pelosi A, Walmsley AM. Current status of plant-made vaccines for veterinary purposes. Expert Rev Vaccines 2014; 9:971-82. [DOI: 10.1586/erv.10.87] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
14
|
Pelosi A, Piedrafita D, De Guzman G, Shepherd R, Hamill JD, Meeusen E, Walmsley AM. The effect of plant tissue and vaccine formulation on the oral immunogenicity of a model plant-made antigen in sheep. PLoS One 2012; 7:e52907. [PMID: 23285224 PMCID: PMC3527624 DOI: 10.1371/journal.pone.0052907] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2012] [Accepted: 11/23/2012] [Indexed: 11/23/2022] Open
Abstract
Antigen-specific antibody responses against a model antigen (the B subunit of the heat labile toxin of enterotoxigenic Escherichia coli, LTB) were studied in sheep following oral immunisation with plant-made and delivered vaccines. Delivery from a root-based vehicle resulted in antigen-specific immune responses in mucosal secretions of the abomasum and small intestine and mesenteric lymph nodes. Immune responses from the corresponding leaf-based vaccine were more robust and included stimulation of antigen-specific antibodies in mucosal secretions of the abomasum. These findings suggest that oral delivery of a plant bioencapsulated antigen can survive passage through the rumen to elicit mucosal and systemic immune responses in sheep. Moreover, the plant tissue used as the vaccine delivery vehicle affects the magnitude of these responses.
Collapse
Affiliation(s)
- Assunta Pelosi
- School of Biological Sciences, Monash University, Clayton, Victoria, Australia
| | | | | | | | | | | | | |
Collapse
|
15
|
Khalafalla RE, Daugschies A, Dyachenko V. Cross-reactivity of anti-Eimeria tenella antibody fragments on merozoites and sporozoites of different chicken Eimeria species. Parasitol Res 2011; 108:745-9. [PMID: 21107860 DOI: 10.1007/s00436-010-2171-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2010] [Accepted: 11/12/2010] [Indexed: 11/26/2022]
Abstract
Eimeria tenella-specific antibodies were examined for the cross-reactivity on the sporozoites and merozoites of E. tenella, Eimeria maxima, Eimeria acervulina and Eimeria brunetti in an indirect fluorescence antibody test. Two of nine antibodies showed cross-reactivity with sporozoites of E. maxima, E. acervulina and E. brunetti; however, the localization of specific fluorescence differed between species. No antibody binding was observed on merozoites. The suitability of these antibodies to alter the infectivity of Eimeria sporozoites and/or merozoites must be verified in cell culture models and in vivo experimental infections.
Collapse
Affiliation(s)
- Reda E Khalafalla
- Institute of Parasitology, Faculty of Veterinary Medicine, University Leipzig, Leipzig, Germany.
| | | | | |
Collapse
|
16
|
Floss DM, Mockey M, Zanello G, Brosson D, Diogon M, Frutos R, Bruel T, Rodrigues V, Garzon E, Chevaleyre C, Berri M, Salmon H, Conrad U, Dedieu L. Expression and immunogenicity of the mycobacterial Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy. J Biomed Biotechnol 2010; 2010:274346. [PMID: 20414351 PMCID: PMC2855997 DOI: 10.1155/2010/274346] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Accepted: 01/15/2010] [Indexed: 12/02/2022] Open
Abstract
This study explored a novel system combining plant-based production and the elastin-like peptide (ELP) fusion strategy to produce vaccinal antigens against tuberculosis. Transgenic tobacco plants expressing the mycobacterial antigens Ag85B and ESAT-6 fused to ELP (TBAg-ELP) were generated. Purified TBAg-ELP was obtained by the highly efficient, cost-effective, inverse transition cycling (ICT) method and tested in mice. Furthermore, safety and immunogenicity of the crude tobacco leaf extracts were assessed in piglets. Antibodies recognizing mycobacterial antigens were produced in mice and piglets. A T-cell immune response able to recognize the native mycobacterial antigens was detected in mice. These findings showed that the native Ag85B and ESAT-6 mycobacterial B- and T-cell epitopes were conserved in the plant-expressed TBAg-ELP. This study presents the first results of an efficient plant-expression system, relying on the elastin-like peptide fusion strategy, to produce a safe and immunogenic mycobacterial Ag85B-ESAT-6 fusion protein as a potential vaccine candidate against tuberculosis.
Collapse
MESH Headings
- Animals
- Antibodies, Bacterial/blood
- Antigens, Bacterial/biosynthesis
- Antigens, Bacterial/genetics
- Antigens, Bacterial/immunology
- Bacterial Proteins/biosynthesis
- Bacterial Proteins/genetics
- Bacterial Proteins/immunology
- Blotting, Western
- Cattle
- Cell Growth Processes/genetics
- Cell Survival/genetics
- Elastin/genetics
- Enzyme-Linked Immunosorbent Assay
- Flow Cytometry
- Hypersensitivity, Delayed
- Mice
- Mice, Inbred BALB C
- Mycobacterium tuberculosis/genetics
- Peptides/genetics
- Plant Leaves/chemistry
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/metabolism
- Recombinant Fusion Proteins/biosynthesis
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Recombinant Fusion Proteins/isolation & purification
- Spleen/cytology
- Swine
- Nicotiana/genetics
- Nicotiana/metabolism
- Vaccines, Synthetic/biosynthesis
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- Doreen Manuela Floss
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, 06466 Gatersleben, Germany
- Institute of Biochemistry, Christian Albrechts University, Olshausenstrasse 40, 24118 Kiel, Germany
| | | | - Galliano Zanello
- Institut National de la Recherche Agronomique (INRA), UR1282, Infectiologie Animale et Santé Publique, 37380, Nouzilly (Tours), France
| | - Damien Brosson
- Laboratoire “Microorganismes: Génome et Environnement” (LMGE), Equipe Interactions Hôtes-Parasites, 24, avenue des landais, 63177 Aubière Cedex, France
| | - Marie Diogon
- Laboratoire “Microorganismes: Génome et Environnement” (LMGE), Equipe Interactions Hôtes-Parasites, 24, avenue des landais, 63177 Aubière Cedex, France
| | | | - Timothée Bruel
- Institut National de la Recherche Agronomique (INRA), UR1282, Infectiologie Animale et Santé Publique, 37380, Nouzilly (Tours), France
| | | | | | - Claire Chevaleyre
- Institut National de la Recherche Agronomique (INRA), UR1282, Infectiologie Animale et Santé Publique, 37380, Nouzilly (Tours), France
| | - Mustapha Berri
- Institut National de la Recherche Agronomique (INRA), UR1282, Infectiologie Animale et Santé Publique, 37380, Nouzilly (Tours), France
| | - Henri Salmon
- Institut National de la Recherche Agronomique (INRA), UR1282, Infectiologie Animale et Santé Publique, 37380, Nouzilly (Tours), France
| | - Udo Conrad
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, 06466 Gatersleben, Germany
| | | |
Collapse
|
17
|
Abstract
Plant-derived biologicals for use in animal health are becoming an increasingly important target for research into alternative, improved methods for disease control. Although there are no commercial products on the market yet, the development and testing of oral, plant-based vaccines is now beyond the proof-of-principle stage. Vaccines, such as those developed for porcine transmissible gastroenteritis virus, have the potential to stimulate both mucosal and systemic, as well as, lactogenic immunity as has already been seen in target animal trials. Plants are a promising production system, but they must compete with existing vaccines and protein production platforms. In addition, regulatory hurdles will need to be overcome, and industry and public acceptance of the technology are important in establishing successful products.
Collapse
Affiliation(s)
- R W Hammond
- USDA-ARS, BARC-West, Rm.252, Bldg. 011, Beltsville, MD 20705, USA.
| | | |
Collapse
|
18
|
Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009; 27:449-67. [PMID: 19356740 PMCID: PMC7126855 DOI: 10.1016/j.biotechadv.2009.03.006] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2008] [Revised: 03/27/2009] [Accepted: 03/31/2009] [Indexed: 12/12/2022]
Abstract
Plants have been identified as promising expression systems for commercial production of vaccine antigens. In phase I clinical trials several plant-derived vaccine antigens have been found to be safe and induce sufficiently high immune response. Thus, transgenic plants, including edible plant parts are suggested as excellent alternatives for the production of vaccines and economic scale-up through cultivation. Improved understanding of plant molecular biology and consequent refinement in the genetic engineering techniques have led to designing approaches for high level expression of vaccine antigens in plants. During the last decade, several efficient plant-based expression systems have been examined and more than 100 recombinant proteins including plant-derived vaccine antigens have been expressed in different plant tissues. Estimates suggest that it may become possible to obtain antigen sufficient for vaccinating millions of individuals from one acre crop by expressing the antigen in seeds of an edible legume, like peanut or soybean. In the near future, a plethora of protein products, developed through ‘naturalized bioreactors’ may reach market. Efforts for further improvements in these technologies need to be directed mainly towards validation and applicability of plant-based standardized mucosal and edible vaccines, regulatory pharmacology, formulations and the development of commercially viable GLP protocols. This article reviews the current status of developments in the area of use of plants for the development of vaccine antigens.
Collapse
Affiliation(s)
| | | | | | - Rakesh Tuli
- Corresponding author. National Botanical Research Institute, Council of Scientific and Industrial Research, Rana Pratap Marg, Lucknow-226001 (U.P.) India. Tel.: +91 522 2205848; fax: +91 522 2205839.
| |
Collapse
|
19
|
Joensuu JJ, Niklander-Teeri V, Brandle JE. Transgenic plants for animal health: plant-made vaccine antigens for animal infectious disease control. PHYTOCHEMISTRY REVIEWS : PROCEEDINGS OF THE PHYTOCHEMICAL SOCIETY OF EUROPE 2008; 7:553-577. [PMID: 32214922 PMCID: PMC7089046 DOI: 10.1007/s11101-008-9088-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2007] [Accepted: 02/05/2008] [Indexed: 05/19/2023]
Abstract
A variety of plant species have been genetically modified to accumulate vaccine antigens for human and animal health and the first vaccine candidates are approaching the market. The regulatory burden for animal vaccines is less than that for human use and this has attracted the attention of researchers and companies, and investment in plant-made vaccines for animal infectious disease control is increasing. The dosage cost of vaccines for animal infectious diseases must be kept to a minimum, especially for non-lethal diseases that diminish animal welfare and growth, so efficient and economic production, storage and delivery are critical for commercialization. It has become clear that transgenic plants are an economic and efficient alternative to fermentation for large-scale production of vaccine antigens. The oral delivery of plant-made vaccines is particularly attractive since the expensive purification step can be avoided further reducing the cost per dose. This review covers the current status of plant-produced vaccines for the prevention of disease in animals and focuses on barriers to the development of such products and methods to overcome them.
Collapse
Affiliation(s)
- J. J. Joensuu
- Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3
| | - V. Niklander-Teeri
- Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland
| | - J. E. Brandle
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3
| |
Collapse
|
20
|
Abubakar M, Sanda A, EL-Yuguda A, Baba S. Seroprevalence of Morbillivirus Antibody and Abattoir Survey of One Humped Slaughtered Camels (Camelus dramedarius) in Maiduguri Municipal Abattoir Maiduguri, Nigeria. ACTA ACUST UNITED AC 2007. [DOI: 10.3923/ajsr.2008.85.89] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview. Transgenic Res 2007; 16:315-32. [PMID: 17436059 PMCID: PMC7089296 DOI: 10.1007/s11248-007-9095-x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2007] [Accepted: 03/19/2007] [Indexed: 11/29/2022]
Abstract
During the past two decades, antibodies, antibody derivatives and vaccines have been developed for therapeutic and diagnostic applications in human and veterinary medicine. Numerous species of dicot and monocot plants have been genetically modified to produce antibodies or vaccines, and a number of diverse transformation methods and strategies to enhance the accumulation of the pharmaceutical proteins are now available. Veterinary applications are the specific focus of this article, in particular for pathogenic viruses, bacteria and eukaryotic parasites. We focus on the advantages and remaining challenges of plant-based therapeutic proteins for veterinary applications with emphasis on expression platforms, technologies and economic considerations.
Collapse
Affiliation(s)
- Doreen Manuela Floss
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, Gatersleben, 06466 Germany
| | | | - Udo Conrad
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, Gatersleben, 06466 Germany
| |
Collapse
|
22
|
Companjen AR, Florack DEA, Slootweg T, Borst JW, Rombout JHWM. Improved uptake of plant-derived LTB-linked proteins in carp gut and induction of specific humoral immune responses upon infeed delivery. FISH & SHELLFISH IMMUNOLOGY 2006; 21:251-60. [PMID: 16464614 DOI: 10.1016/j.fsi.2005.12.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2005] [Revised: 08/10/2005] [Accepted: 12/08/2005] [Indexed: 05/06/2023]
Abstract
Oral vaccination of fish is an effortless and stress free immunisation method which can be used for almost any age. However, vaccination via the mucosal route does have disadvantages. For example, the vaccine may induce tolerance and has to be protected to escape digestion. Also the vaccine should be efficiently delivered to immune-competent cells in the gut or other lymphoid organs. In addition, it should be cost effective. Here we present a novel fish vaccination model using potato tubers as vaccine production and delivery system. The model vaccines discussed here include fusion proteins consisting of a gut adhesion molecule (LTB) and a viral peptide or green fluorescent protein (GFP) expressed in potato tubers. The adhesion molecule mediates binding to and uptake from the gut, whereas the viral peptide or GFP functions as model vaccine antigen provoking the induction of an immune response. We demonstrate that fusion to LTB facilitates an elevated uptake of the model vaccines in carp gut mucosa. The plant-derived fusion proteins also elicit a specific systemic humoral immune response upon oral application of crude tuber material incorporated into a standard dietary feed pellet. The data presented here show the promising potentials of the plant as a production system for oral vaccines in aquaculture and feed mediated immunisation of fish.
Collapse
Affiliation(s)
- A R Companjen
- Cell Biology and Immunology Group, Department of Animal Sciences, PO Box 338, Wageningen University and Research Centre, 6700 AH Wageningen, The Netherlands
| | | | | | | | | |
Collapse
|
23
|
Ashraf S, Singh P, Yadav DK, Shahnawaz M, Mishra S, Sawant SV, Tuli R. High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol 2005; 119:1-14. [PMID: 16038998 PMCID: PMC7114349 DOI: 10.1016/j.jbiotec.2005.06.009] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2005] [Revised: 05/23/2005] [Accepted: 06/02/2005] [Indexed: 11/29/2022]
Abstract
A synthetic gene coding for the surface glycoprotein (G protein) of rabies virus was strategically designed to achieve high-level expression in transgenic plants. The native signal peptide was replaced by that of the pathogenesis related protein, PR-S of Nicotiana tabacum. An endoplasmic reticulum retention signal was included at C-terminus of the G protein. Tobacco plants were genetically engineered by nuclear transformation. Selected transgenic lines expressed the chimeric G protein at 0.38% of the total soluble leaf protein. Mice immunized intraperitoneally with the G protein purified from tobacco leaf microsomal fraction elicited high level of immune response as compared to the inactivated commercial viral vaccine. The plant-derived G protein induced complete protective immunity in mice against intracerebral lethal challenge with live rabies virus. The results establish that plants can provide a safe and effective production system for the expression of immunoprotective rabies virus surface protein.
Collapse
Affiliation(s)
- Shadma Ashraf
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| | - P.K. Singh
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| | - Dinesh K. Yadav
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| | - Md. Shahnawaz
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| | - Satish Mishra
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| | - Samir V. Sawant
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| | - Rakesh Tuli
- National Botanical Research Institute, Rana Pratap Marg, Lucknow 226001, India
| |
Collapse
|
24
|
Webster DE, Thomas MC, Pickering R, Whyte A, Dry IB, Gorry PR, Wesselingh SL. Is there a role for plant‐made vaccines in the prevention of HIV/AIDS? Immunol Cell Biol 2005; 83:239-47. [PMID: 15877601 DOI: 10.1111/j.1440-1711.2005.01341.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Although educational programs have had some impact, immunization against HIV will be necessary to control the AIDS pandemic. To be effective, vaccination will need to be accessible and affordable, directed against multiple antigens, and delivered in multiple doses. Plant-based vaccines that are heat-stable and easy to produce and administer are suited to this type of strategy. Pilot studies by a number of groups have demonstrated that plant viral expression systems can produce HIV antigens in quantities that are appropriate for use in vaccines. In addition, these plant-made HIV antigens have been shown to be immunogenic. However, given the need for potent cross-clade humoral and T-cell immunity for protection against HIV, and the uncertainty surrounding the efficacy of protein subunit vaccines, it is most likely that plant-made HIV vaccines will find their niche as booster immunizations in prime-boost vaccination schedules.
Collapse
MESH Headings
- Acquired Immunodeficiency Syndrome/immunology
- Acquired Immunodeficiency Syndrome/prevention & control
- Animals
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- HIV Infections/immunology
- HIV Infections/prevention & control
- Humans
- Immune Tolerance/immunology
- Immunity, Cellular/immunology
- Mice
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/metabolism
- Vaccines, Edible/administration & dosage
- Vaccines, Edible/biosynthesis
- Vaccines, Edible/genetics
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/biosynthesis
- Vaccines, Synthetic/genetics
- Viral Proteins/genetics
- Viral Proteins/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/biosynthesis
- Viral Vaccines/genetics
Collapse
Affiliation(s)
- Diane E Webster
- Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia.
| | | | | | | | | | | | | |
Collapse
|
25
|
Sinnathamby G, Seth S, Nayak R, Shaila MS. Cytotoxic T cell epitope in cattle from the attachment glycoproteins of rinderpest and peste des petits ruminants viruses. Viral Immunol 2004; 17:401-10. [PMID: 15357906 DOI: 10.1089/vim.2004.17.401] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The surface glycoproteins of rinderpest virus (RPV) confer protective immunity in cattle. We demonstrated that cattle immunized with a recombinant extracellular baculovirus expressing the hemagglutinin (H) protein of RPV (rECV-H) generate virus neutralizing antibody responses, bovine leukocyte antigen (BoLA) class II restricted helper T cell responses and BoLA class I restricted cytotoxic T cell (CTL) responses against RPV-H and hemagglutinin-neuraminidase (HN) glycoprotein of closely related Peste des petits ruminants virus (PPRV). In this study, employing autologous skin fibroblasts transiently expressing truncations of H and HN in a BoLA class I restricted lymphoproliferation assay, we have mapped a highly homologous domain (amino acids 400-423) on these proteins harboring a CTL epitope. Subsequently, based on sequence comparison with available BoLA class I binding motifs, we have identified a BoLA-A11 binding motif (amino acids 408-416) in the stimulatory domain. Autologous cells pulsed with a synthetic peptide corresponding to this sequence stimulated CTLs from rECV-H immunized as well as tissue culture attenuated RPV vaccinated cattle of different breeds and parentage. This is the first epitope identified in cattle on the attachment glycoproteins of RPV and PPRV.
Collapse
Affiliation(s)
- G Sinnathamby
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India
| | | | | | | |
Collapse
|
26
|
Zhou JY, Cheng LQ, Zheng XJ, Wu JX, Shang SB, Wang JY, Chen JG. Generation of the transgenic potato expressing full-length spike protein of infectious bronchitis virus. J Biotechnol 2004; 111:121-30. [PMID: 15219399 PMCID: PMC9212530 DOI: 10.1016/j.jbiotec.2004.03.012] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2003] [Revised: 03/01/2004] [Accepted: 03/03/2004] [Indexed: 11/17/2022]
Abstract
To seek a new delivery system of vaccine for infectious bronchitis virus (IBV), transgenic potato expressing full-length spike (S) protein of IBV was produced and its immunogenicity in chickens was investigated. One to three copies of S gene of IBV were randomly and stably inserted into potato (Solanum tuberrosum cv. Dongnong 303) genome by Agrobacterium tumefaciens-mediated transformation. Transcription and translation of S gene for IBV were confirmed by Northern blot and Western blot analyses in transgenic plantlets. Chickens immunized orally and intramuscularly with transgenic potato tubers expressing S protein generated the detectable levels of serum neutralizing antibodies and were protected against the challenge with the virulent IBV. In vitro secretion of interleukin 2 and T lymphocyte proliferation of spleen cells from the immunized chickens varied with the dose and the manner of vaccination with S protein derived from transgenic plants. The results indicated that S protein expressed in transgenic plants might be a new source for the production of Coronaviridae IBV vaccine.
Collapse
Affiliation(s)
- Ji-Yong Zhou
- Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310029, China.
| | | | | | | | | | | | | |
Collapse
|
27
|
Khandelwal A, Renukaradhya GJ, Rajasekhar M, Sita GL, Shaila MS. Systemic and oral immunogenicity of hemagglutinin protein of rinderpest virus expressed by transgenic peanut plants in a mouse model. Virology 2004; 323:284-91. [PMID: 15193924 DOI: 10.1016/j.virol.2004.02.030] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2002] [Revised: 02/28/2003] [Accepted: 02/23/2004] [Indexed: 10/26/2022]
Abstract
Rinderpest causes a devastating disease, often fatal, in wild and domestic ruminants. It has been eradicated successfully using a live, attenuated vaccine from most part of the world leaving a few foci of disease in parts of Africa, the Middle East, and South Asia. We have developed transgenic peanut (Arachis hypogaea L.) plants expressing hemagglutinin (H) protein of rinderpest virus (RPV), which is antigenically authentic. In this work, we have evaluated the immunogenicity of peanut-expressed H protein using mouse model, administered parenterally as well as orally. Intraperitoneal immunization of mice with the transgenic peanut extract elicited antibody response specific to H. These antibodies neutralized virus infectivity in vitro. Oral immunization of mice with transgenic peanut induced H-specific serum IgG and IgA antibodies. The systemic and oral immunogenicity of plant-derived H in absence of any adjuvant indicates the potential of edible vaccine for rinderpest.
Collapse
Affiliation(s)
- Abha Khandelwal
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, India
| | | | | | | | | |
Collapse
|